CJC-1295 DAC 5mg: What the Vial Contains and How It Works

CJC-1295 DAC 5mg refers to a nominal 5 mg amount of an albumin-binding GHRH analog. It is not a 5 mg dose recommendation. Human research established a long pharmacokinetic profile and short-term hormone changes, while an approved personal dosing schedule and long-term benefits remain unestablished.

What the DAC Group Changes in CJC-1295

The material marketed as CJC-1295 no DAC or Mod GRF (1-29) lacks the albumin-binding modification and is distinct from the DAC compound studied in the cited human trials. FDA’s assessment cautions against transferring the DAC pharmacological profile to non-DAC forms; it does not establish a universal 30-minute human half-life or a daily regimen for all such products.

• The approximately 6–8-day figure comes from healthy human adults given the DAC compound: Teichman and colleagues estimated a half-life of 5.8–8.1 days after a single subcutaneous administration. It is not an animal-only estimate or a value established for every product labeled CJC-1295.
• Albumin binding changes exposure, but the resulting half-life does not prescribe an injection interval. Study schedules and retail label amounts must be considered separately.
• A 2 mg, 5 mg, or 10 mg label is a claimed peptide amount, not a recommended dose or proof of actual content. Bachem explains that chromatographic purity and net peptide content are different measurements; salts, water, and other material can affect how vial mass relates to peptide amount.
• Sustained stimulation does not mean GH pulses disappear. Ionescu and Frohman’s human sampling study found increased trough and mean GH with preserved pulse frequency and magnitude one week after CJC-1295 DAC. Calling the response a flat, nonpulsatile “GH bleed” misrepresents that result.

A larger nominal vial amount changes the material available for an assay; it does not identify a different mechanism or prove the most economical format.

How to Reconstitute CJC-1295 DAC 5mg

For laboratory reconstitution, use the exact material’s validated method, compatible diluent, and container capacity. Bacteriostatic water is not a universal requirement: its product labeling describes preserved water, but does not establish compatibility or a storage life for CJC-1295 DAC.

The following calculations assume the stated peptide mass is accurate, dissolution is complete, and the specified volume is the final solution volume. They illustrate laboratory concentration and aliquot arithmetic, not a recommended human amount. Added diluent is only an approximation to final volume, and vessel capacity must be checked.

Storage temperature and use-by time depend on the peptide formulation, solvent, concentration, container, and validated stability data. There is no universal “refrigerate for four weeks” or “freeze at −20°C” rule for every retail CJC-1295 vial. CDC’s opened multidose-vial guidance is not evidence that a newly mixed peptide remains chemically stable for 28 days.

Reported CJC-1295 DAC Dosage and Cycle Length

There is no FDA-approved CJC-1295 DAC dose or validated bodybuilding regimen. A fixed 1–2 mg weekly range should not be presented as the dose established by the original weight-based human trials. Research exposure cannot be converted into a safe personal amount from age, sex, weight, or vial size alone.

• Single-dose study cohorts: 30, 60, 125, and 250 mcg/kg under trial monitoring.
• Repeat-dose study: two or three administrations at weekly or biweekly intervals.
• Clinical limitation: neither design validated an eight- or twelve-week fitness cycle.
• A half-life describes an approximately 50% concentration decline under the studied conditions, not the time until all drug is gone or every adverse effect resolves. Repeat exposure, assay detection limits, and individual pharmacokinetics prevent a single “fully cleared by” date.

No defined set of original Reddit posts, dates, verified products, or participant records is supplied here, so this article cannot rank common protocols or describe a forum consensus. A post can identify a claim worth checking, but does not establish its frequency, cause, or safety.

CJC-1295 With DAC vs Without DAC vs Ipamorelin

Ipamorelin acts through the ghrelin receptor pathway, whereas CJC-1295 acts through the GHRH receptor pathway. Different mechanisms do not establish a safe combination dose, compatibility in one vial, or superior sleep, recovery, or body composition. The cited DAC trials did not validate the online CJC-1295/ipamorelin schedules.

Sustained stimulation does not mean GH pulses disappear. Ionescu and Frohman’s human sampling study found increased trough and mean GH with preserved pulse frequency and magnitude one week after CJC-1295 DAC. Calling the response a flat, nonpulsatile “GH bleed” misrepresents that result.

Safety, Sourcing, and Legal Status

CJC-1295 has no FDA-approved human indication. A “research use only” label does not itself authorize human treatment or settle whether a particular sale, import, or possession is lawful. Product claims, intended use, compounding requirements, and jurisdiction matter; an ordinary retail research vial is not an approved prescription medicine.

The short human studies reported injection-site reactions, flushing or warmth, headache, and gastrointestinal symptoms. FDA also identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes limited clinical data and impurity/immunogenicity concerns. Neither a tolerable first exposure nor a normal blood test establishes long-term safety.

A lot-matched report can document the sample tested, method, date, and result. It does not prove every vial has the same content, that a supplier-submitted sample was independently purchased, or that the material is sterile or clinically safe. Acceptance criteria should follow the laboratory’s intended assay, rather than a universal 98% purity threshold. Related research also covers CJC-1295 With DAC vs Without DAC: What's the Difference?.